Hematological Disorders

ASH 2021,which ended on December 14, 2021, was a premier event in malignant and non-malignant hematology. Like every year, key pharma players took center stage and shared new data regarding the development of their primary candidates in cancer and blood disorders, showcasing the impact of ongoing research. DelveInsight, maintaining an essence of brevity, has compiled the conference’s major highlights so that you do not miss out on these expansions in hematology. Diffuse Large B-cell Lymphoma/ Large B-cell lymphoma (LBCL) Highlights: ASH 2021 Key pharma companies involved in presenting their DLBCL/LBCL data readouts during the conference included Roche, Novartis,...